Procaps Group S.A. (PROC)

Market Cap	412.94M
Revenue (ttm)	406.09M
Net Income (ttm)	66.59M
Shares Out	112.82M
EPS (ttm)	0.66
PE Ratio	5.55
Forward PE	25.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,904
Open	3.70
Previous Close	3.53
Day's Range	3.61 - 3.70
52-Week Range	3.50 - 7.75
Beta	0.05
Analysts	Hold
Price Target	4.50 (+22.95%)
Earnings Date	Nov 13, 2023

About PROC

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1976
• Employees: 5,500
• Stock Exchange: NASDAQ
• Ticker Symbol: PROC

Analyst Forecast

According to one analyst, the rating for PROC stock is "Hold" and the 12-month stock price forecast is $4.5.

Price Target

$4.5

(22.95% upside)

Analyst Consensus: Hold